Recent transcriptome studies using next-generation sequencing have detected aberrant changes in the expression of noncoding RNAs (ncRNAs) associated with cancer. For prostate cancer, the expression levels of ncRNAs including microRNAs and long noncoding RNAs are strongly associated with diagnosis, carcinogenesis and tumor growth.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Moreover, androgen and its cognate receptor, androgen receptor (AR), regulate various signaling pathways for prostate tumor growth. In addition, progression to lethal castration-resistant prostate cancer (CRPC) is also owing to AR function. Systematic analysis of AR-binding sites and their regulated transcripts revealed that many ncRNAs are widely regulated at the transcriptional level. Thus, recent studies provide new insight into the complicated molecular mechanism of prostate cancer progression. This review focused on the role of various ncRNAs in prostate cancer and the association between their expression and CRPC.
Briefings in functional genomics. 2015 Dec 17 [Epub ahead of print]
Ken-Ichi Takayama, Satoshi Inoue